Thermo Fisher Scientific acquires PeproTech in USD $1.85 billion deal

Written by Amy White

Thermo Fisher Scientific Inc. (MA, USA) has acquired PeproTech (NJ, USA), integrating PeproTech’s portfolio into Thermo Fisher’s Life Sciences Solutions Segment. With a focus in developing, manufacturing and selling research-use only and GMP cytokines, PeproTech provides recombinant proteins, including growth factors for scientists and researchers. These recombinant proteins are applied in the development and manufacturing of cell and gene therapies, mainly for utilization in cellular research models. Marc N Casper, Chairman, President and CEO of Thermo Fisher Scientific, commented: “In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive...

To view this content, please register now for access

It's completely free